Cellectis (NASDAQ:CLLS) Given "Sell (D-)" Rating at Weiss Ratings

Key Points

• Cellectis (NASDAQ:CLLS) has been given a reaffirmed "sell (D-)" rating by Weiss Ratings, indicating a negative outlook on the stock.
• In contrast, Wall Street Zen recently upgraded Cellectis to a "hold" rating, with a consensus price target of $4.00 among analysts.
• Cellectis reported earnings of ($0.24) per share, missing estimates, but exceeded revenue expectations with $18.19 million for the quarter.

Cellectis (NASDAQ:CLLS - Get Free Report)'s stock had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings in a research report issued on Wednesday,Weiss Ratings reports.

Separately, Wall Street Zen raised Cellectis to a "hold" rating in a research report on Saturday, September 20th. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus price target of $4.00.

Cellectis Stock Performance

CLLS traded up $0.48 on Wednesday, reaching $4.30. The company had a trading volume of 554,524 shares, compared to its average volume of 151,754. Cellectis has a 1 year low of $1.10 and a 1 year high of $4.59. The stock has a market capitalization of $212.33 million, a PE ratio of -5.24 and a beta of 3.10. The company has a quick ratio of 1.38, a current ratio of 1.38 and a debt-to-equity ratio of 0.58. The stock has a 50-day moving average price of $2.97 and a 200-day moving average price of $2.04.

Cellectis (NASDAQ:CLLS - Get Free Report) last announced its quarterly earnings results on Monday, August 4th. The biotechnology company reported ($0.24) earnings per share for the quarter, missing analysts' consensus estimates of ($0.15) by ($0.09). The company had revenue of $18.19 million during the quarter, compared to analysts' expectations of $10.07 million. Cellectis had a negative net margin of 100.69% and a negative return on equity of 68.05%. As a group, research analysts forecast that Cellectis will post -0.46 EPS for the current fiscal year.

Institutional Trading of Cellectis

Several large investors have recently modified their holdings of the business. OLD Mission Capital LLC acquired a new stake in shares of Cellectis in the first quarter valued at approximately $31,000. Acadian Asset Management LLC grew its position in shares of Cellectis by 132.9% in the first quarter. Acadian Asset Management LLC now owns 46,377 shares of the biotechnology company's stock valued at $55,000 after purchasing an additional 26,461 shares during the last quarter. Long Focus Capital Management LLC grew its position in shares of Cellectis by 2.2% in the first quarter. Long Focus Capital Management LLC now owns 4,717,293 shares of the biotechnology company's stock valued at $5,849,000 after purchasing an additional 100,000 shares during the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in shares of Cellectis by 228.4% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 4,722,664 shares of the biotechnology company's stock valued at $5,856,000 after purchasing an additional 3,284,409 shares during the last quarter. 63.90% of the stock is currently owned by institutional investors and hedge funds.

About Cellectis

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.